Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Liabilities and Shareholders Equity (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Liabilities and Shareholders Equity data on record, last reported at $47.1 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 12.94% year-over-year to $47.1 million; the TTM value through Dec 2025 reached $169.3 million, down 17.56%, while the annual FY2025 figure was $47.1 million, 12.94% down from the prior year.
  • Liabilities and Shareholders Equity reached $47.1 million in Q4 2025 per VRCA's latest filing, up from $40.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $108.1 million in Q1 2021 and bottomed at $32.9 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $64.5 million, with a median of $62.8 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 97.67% in 2023, then tumbled 66.11% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $80.1 million in 2021, then tumbled by 44.19% to $44.7 million in 2022, then skyrocketed by 82.46% to $81.6 million in 2023, then crashed by 33.66% to $54.1 million in 2024, then fell by 12.94% to $47.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $47.1 million in Q4 2025, $40.9 million in Q3 2025, and $39.1 million in Q2 2025.